Prevalence of BK Viremia in Simultaneous Liver-Kidney Transplant

Part of paid clinical trials in Dallas, Texas.

Sponsor
Methodist Health System
Study ID
NCT05224583
Status
Enrolling By Invitation

Conditions

  • BK Viremia
  • Kidney Transplant Infection
  • Liver Transplant Infection
  • Polyomavirus Infections

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • Simultaneous Liver-Kidney Transplant — PROCEDURE
    Simultaneous Liver-Kidney Transplant

Study Details

The human BK polyomavirus is a significant risk factor for renal transplant dysfunction and allograft loss. The prevalence of BK viremia (BKV) following kidney transplantation is estimated to be 10-20%.

Key Dates

First listed
Feb 4, 2022
Start date
Nov 17, 2021
Status verified
Jan 2026
Primary completion
Nov 17, 2027
Completion
Nov 17, 2028

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: Simultaneous Liver-Kidney Transplant patients population at MDMC
    Consecutive SLK transplant recipients who were transplanted at MDMC over a 6-year period (2015 to 2020).

Primary Outcome Measure

To characterize the prevalence of BKV in the SLK patient population at (Methodist Dallas Medical Center)MDMC. [ Time Frame: over a 6-year period (2015 to 2020). ]

Locations (1)

FacilityCityStateZIPSite coordinators
Methodist Dallas Medical CenterDallasTexas75203-

Find similar trials in Dallas, TX

By research site
Methodist Dallas Medical Center· Dallas, TX

Related Studies